TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has received a consensus rating of “Moderate Buy” from the twelve analysts that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $152.3333.

Several analysts have issued reports on TMDX shares. Wall Street Zen cut TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Oppenheimer lifted their target price on TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Needham & Company LLC upped their price target on shares of TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, JPMorgan Chase & Co. upped their price objective on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th.

TransMedics Group Stock Down 9.2%

Shares of NASDAQ:TMDX opened at $113.21 on Thursday. The firm has a market cap of $3.88 billion, a PE ratio of 23.10 and a beta of 1.98. The company has a fifty day simple moving average of $135.25 and a 200 day simple moving average of $127.36. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06. TransMedics Group has a 12-month low of $62.23 and a 12-month high of $156.00.

Insider Buying and Selling at TransMedics Group

In related news, Director Stephanie Lovell sold 1,193 shares of TransMedics Group stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total value of $178,496.66. Following the transaction, the director directly owned 2,866 shares in the company, valued at $428,810.92. The trade was a 29.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Gerardo Hernandez sold 7,236 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total value of $1,065,211.56. Following the completion of the transaction, the chief financial officer owned 14,689 shares of the company’s stock, valued at $2,162,367.69. This trade represents a 33.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 16,205 shares of company stock worth $2,353,002. 7.00% of the stock is owned by insiders.

Hedge Funds Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently bought and sold shares of the business. Whittier Trust Co. of Nevada Inc. grew its position in TransMedics Group by 981.0% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares in the last quarter. Salomon & Ludwin LLC bought a new stake in TransMedics Group in the third quarter worth $28,000. Harvest Fund Management Co. Ltd bought a new stake in shares of TransMedics Group during the 3rd quarter worth about $29,000. Allworth Financial LP grew its holdings in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the last quarter. Finally, Optiver Holding B.V. grew its stake in TransMedics Group by 248.1% in the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after buying an additional 191 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.